Anti-Rad51 Antibody (A351)

Anti-Rad51 Antibody

HT29 cells. RAD51 immunofluorescence analysis in parental and resistant HT29 cells under basal conditions or following treatment with targeted therapy consisting of BRAFi dabrafenib (4 µM, 24 h) and EGFRi cetuximab (5 µg/mL, 24 h). Hydroxyurea (HU; 2.5 mM, 24 h) was used as a positive control for replication stress and DNA damage induction. Cells were seeded on coverslips, stained for RAD51, and nuclei were counterstained with DRAQ-5. Data are presented as mean ± SEM from n = 3 independent biological experiments (at least 5 independent fields quantified per experiment, corresponding to approximately 100 nuclei per biological replicate). Images were acquired using a Leica Stellaris confocal microscope equipped with a 63× oil-immersion objective (NA 1.4) under identical acquisition settings. Scale bar = 25 µm. Statistical significance was assessed using one-way ANOVA with Tukey’s multiple-comparisons test.

HCA46 cells. RAD51 immunofluorescence analysis in parental and resistant HCA46 cells under basal conditions or following treatment with EGFRi cetuximab (25 µg/mL, 24 h). Hydroxyurea (HU; 2.5 mM, 24 h) was used as a positive control for replication stress and DNA damage induction. Cells were seeded on coverslips, stained for RAD51, and nuclei were counterstained with DRAQ-5. Data are presented as mean ± SEM from n = 3 independent biological experiments (at least 5 independent fields quantified per experiment, corresponding to approximately 100 nuclei per biological replicate). Images were acquired using a Leica Stellaris confocal microscope equipped with a 63× oil-immersion objective (NA 1.4) under identical acquisition settings. Scale bar = 25 µm. Statistical significance was assessed using one-way ANOVA with Tukey’s multiple-comparisons test.